Health

Gout incidence down with SGLT2 inhibitors in type 2 diabetes

Adults with type 2 diabetes newly prescribed a sodium-glucose cotransporter-2 (SGLT2) inhibitor have a lower incidence of gout than those prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist, according to a study ...

Diseases, Conditions, Syndromes

What do you know about rheumatic diseases?

September is Rheumatic Disease Awareness Month, which makes this a good time to learn about four common rheumatic diseases: Ankylosing spondylitis, gout, juvenile idiopathic arthritis and lupus.

Diabetes

Gout linked to heightened diabetes risk

Gout is linked to a heightened risk of type 2 diabetes, suggests research published online in the Annals of the Rheumatic Diseases. The magnitude of the association seems to be significantly greater in women, among whom the ...

Health

Vitamin C does not lower uric acid levels in gout patients

Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients ...

Genetics

Gout study offers genetic insight into 'disease of kings'

Scientists have shed light on why some people are more susceptible to gout than others. A study has identified 18 new genetic variations that increase levels of uric acid in the blood, which is the main cause of the disease. ...

Arthritis & Rheumatism

FDA: Gout drug uloric increases risk of death

(HealthDay)—The gout medicine Uloric (febuxostat) carries a higher risk of death than allopurinol, according to the U.S. Food and Drug Administration.

Arthritis & Rheumatism

Study identifies potential new target for treatment of gout

Researchers at Washington State University Health Sciences Spokane and elsewhere have identified a new therapeutic target for the treatment of gout, a common type of arthritis that causes episodes of painful and stiff joints.

Arthritis & Rheumatism

Should clinicians reconsider standard therapy for gout?

Gout occurs when urate crystals accumulate in the joints, and xanthine oxidase inhibitors such as febuxostat are a mainstay of therapy to help reduce blood urate levels in affected patients. A recent clinical trial published ...

page 3 from 12